MississippiHB 3142026 Regular SessionHouseWALLET

Ibogaine; authorize SDH to select a consortium to conduct a drug development clinical trial with, to secure FDA's approval of.

Your PRIA Score

Score Hidden

Personalized for You

How does this bill affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Bill Overview

Analyzed Economic Effects

6 provisions identified: 2 benefits, 0 costs, 4 mixed.

Coordinate ibogaine trial with FDA

Beginning July 1, 2026, the selected consortium must coordinate its ibogaine trial with the FDA, the lead consortium, and other states. After the lead consortium files an IND and asks for Breakthrough Therapy status, the Mississippi consortium must sign an agreement with that lead group.

State takes 20% of ibogaine profits

Beginning July 1, 2026, at least 20% of revenue from patents, data, protocols, and other rights created by the trial must go to Mississippi’s State General Fund. The interagency contract must also set the state’s revenue share and spell out goals, budget, timeline, partners, and other required terms.

Coverage plans and safety for ibogaine

Beginning July 1, 2026, the proposal must include a full plan to win FDA approval, pursue Breakthrough Therapy status, secure coverage from private insurers, Medicare, Medicaid, and TRICARE, and ensure access for uninsured people after approval. It must cover trial design, heart-safety checks, dosing, aftercare, provider training and credentials, data integrity, and recognizing the state’s commercial interest, plus a plan to build a corporate presence in Mississippi. It must also include financial disclosures proving the consortium can fully match state funds. If the FDA approves ibogaine, a Mississippi-licensed doctor must supervise dosing in a hospital or other licensed health facility while the patient is under the drug.

Ibogaine trial funding needs matches and milestones

Beginning July 1, 2026, the Health Department must sign an interagency contract with the lead university and fund the trial using money the Legislature specifically appropriates. No state money goes out until the consortium secures non-state matching funds that fully match the state amount and the department verifies them. Payments can be released in steps after set goals are met and spending is documented. The department and consortium members may also accept private gifts, grants, and donations.

Regular reports and federal waivers for trial

Beginning July 1, 2026, the consortium must send quarterly progress and financial reports to the Health Department. The department must notify the Legislature after the contract is signed and send an annual progress report by December 1 each year. If a federal waiver or approval is needed, the agency must request it and may delay that part of the law until it is granted.

State launches ibogaine trial program

Beginning July 1, 2026, the Health Department can pick a consortium to run an ibogaine drug-development trial aimed at FDA approval to treat opioid use disorder and related conditions. Each consortium must include the same drug developer used by the lead consortium, plus a Mississippi college or university and a hospital. The selected group must name a lead university to handle contracts and reporting, and it may hire the staff it needs. Trial sites are limited to hospitals and colleges or universities.

Sponsors & Cosponsors

Sponsor

Sam Creekmore IV
House

Cosponsors

William Tracy Arnold
Republican • House
Larry Byrd
Republican • House
Lester Carpenter
Republican • House

Roll Call Votes

All Roll Calls

Yes: 328 • No: 6

House vote • 3/17/2026

Concurred in Amend From Senate

Yes: 115 • No: 3

Senate vote • 3/10/2026

Passed As Amended

Yes: 51 • No: 1

Senate vote • 3/5/2026